- This historic approval provides a new treatment option that reduces the rate of annual bleeds, reduces or eliminates the need for prophylactic therapy and generates elevated and sustained factor IX levels for years after a one-time infusion
- With the approval of HEMGENIX, CSL now offers an even more comprehensive portfolio of treatments for people living with hemophilia B, ushering in a new era of treatment options
Author Archive: AZBio
Student Opportunity – 2023 KEYS Internships
The 2023 KEYS Research Internship applications opened November 21, 2022.Continue reading
Ultrasound activated microbubbles enhance the activity of standard of care therapeutics in pancreatic cancer
PHOENIX, Arizona and OSLO, Norway — November 21, 2022 — Scientists at the Phoenix-based Translational Genomics Research Institute (TGen), part of City of Hope, and EXACT Therapeutics AS (“EXACT-Tx”, Euronext Growth: EXTX), a Norwegian clinical stage precision health company, today report that the ultrasound based Acoustic Cluster Therapy (ACT®) significantly enhanced the antitumor efficacy of standard care therapies in a preclinical model for pancreatic cancer.Continue reading
Five Leaders Elected to the AZBio Board of Directors
Tony Caldwell of Snell & Wilmer, Brandy Flores of Pfizer, Renée Galá of Jazz Pharmaceuticals, Shannon Groppenbacher of Johnson & Johnson, and Nathan Trembath of Bristol Myers Squibb, join the Arizona Bioindustry Association leadership team.Continue reading
New State of Arizona Web Portal Makes It Easier to Launch a Business in Arizona
Newly streamlined Arizona Business One Stop process makes it easy to plan, start and grow a business in the stateContinue reading
FDA Approves First and Only Treatment Indicated to Delay the Onset of Stage 3 Type 1 Diabetes
TZIELD™ (teplizumab-mzwv) approved by FDA as the first and only treatment indicated to delay the onset of Stage 3 type 1 diabetes (T1D) in adult and pediatric patients aged 8 years and older with Stage 2 T1D
New Study Identifies Connection Between Diabetes Medications, Multiple Sclerosis
Researchers at the Center for Innovation in Brain Science examined the impact of medication exposure in people with Type 2 diabetes on the risk of developing multiple sclerosis.
The study found that anti-hyperglycemic medications used to treat Type 2 diabetes resulted in an increased risk of multiple sclerosis for people older than 45, particularly among women.Continue reading
San Tan Tech Center has Move-in Ready Life Science Space Available
San Tan Tech Center is a Life Science project located in Chandler, Arizona just 1 mile west of the Loop 101 freeway at the intersection of McClintock & Chandler Blvd. Currently there is approximately 65,000 SF of life science space in the project with notable users such as the State of Arizona Dept. of Agriculture, Cowper, DHIA and FirstCyte Biologics.Continue reading
New UArizona Health Sciences Center Receives $150M State Investment Plus Philanthropic Support
Arizona Gov. Doug Ducey designated $150 million in new funding for the University of Arizona Health Sciences Center for Advanced Molecular and Immunological Therapies, which also received part of a new $10 million gift from the Steele Foundation.